Login / Signup

Utility of Routine Laboratory Biomarkers to Detect COVID-19: A Systematic Review and Meta-Analysis.

Jana SuklanJames CheaveauSarah HillSamuel G UrwinKile GreenAmanda WinterTimothy HicksAnna E BoathAshleigh KernohanD Ashley PriceA Joy AllenEoin MoloneySara Graziadio
Published in: Viruses (2021)
No routine laboratory biomarkers perform well enough in diagnosing COVID-19 in isolation for them to be used as a standalone diagnostic test or to help clinicians prioritize patients for treatment. Instead, other diagnostic tests are needed. The aim of this work was to statistically summarise routine laboratory biomarker measurements in COVID-19-positive and -negative patients to inform future work. A systematic literature review and meta-analysis were performed. The search included names of commonly used, routine laboratory tests in the UK NHS, and focused on research papers reporting laboratory results of patients diagnosed with COVID-19. A random effects meta-analysis of the standardized mean difference between COVID-19-positive and -negative groups was conducted for each biomarker. When comparing reported laboratory biomarker results, we identified decreased white blood cell, neutrophil, lymphocyte, eosinophil, and platelet counts; while lactate dehydrogenase, aspartate aminotransferase, and alanine aminotransferase were elevated in COVID-19-positive compared to COVID-19-negative patients. Differences were identified across a number of routine laboratory biomarkers between COVID-19-positive and -negative patients. Further research is required to identify whether routine laboratory biomarkers can be used in the development of a clinical scoring system to aid with triage of patients.
Keyphrases
  • coronavirus disease
  • sars cov
  • newly diagnosed
  • clinical practice
  • patient reported outcomes
  • mesenchymal stem cells
  • single cell
  • quality improvement
  • cell therapy
  • chronic kidney disease
  • adverse drug
  • drug induced